Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

Medicine, Oncology, Pharmacology +13

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

David J. Dorer, Ronald K. Knickerbocker, Michele Baccarani et al. · Leukemia Research · 2016 · 159 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS

Huu H. Huynh, Claire Pressiat, Hélène Sauvageon et al. · Therapeutic Drug Monitoring · 2016 · 79 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability

Adnan A. Kadi, Hany W. Darwish, Mohamed W. Attwa et al. · PLoS ONE · 2016 · 35 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +17